Sorafenib

目录号:S7397 别名: BAY 43-9006

Sorafenib Chemical Structure

Molecular Weight(MW): 464.82

Sorafenib是Raf-1, B-Raf和VEGFR-2的多重激酶抑制剂,无细胞试验中IC50分别为6 nM, 22 nM和90 nM。

规格 价格 库存 购买数量  
RMB 1205.41 现货
RMB 2214.52 现货
RMB 5503.41 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献62篇:

客户使用该产品的9个实验数据:

  • Inhibition of the MAPK signaling pathway results in downregulation of Plk-1 protein expression. (a) WB analysis for Plk-1 protein after treatment of human melanoma cell lines M14 and WM-115 with MEK 1/2 inhibitor PD98059 (10 μM), JNK inhibitor (16 μM), p38 inhibitor SB203580 (20 μM), and multikinase inhibitor sorafenib (10 μM) for 48 h showing significant reduction in the expression of Plk-1 protein after 48 hours. (b) Annexin V/PI staining of cells treated with MAPK inhibitors and induction of apoptosis. JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK 1/2, mitogen-activated protein kinase kinase 1/2; Plk-1, polo-like kinase 1; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. Sorafenib purchased from Selleck.

    (A) were exposed to 200 uM gentamicin for various time periods. Immunoreactivity for phosphorylated JNK (green) and c-Jun (blue) in hair cells increased in a time-dependent manner. B. Hair cells from explants pre-treated with 500 nM sorafenib displayed a near complete inhibition of JNK activation at all time points analyzed.

    J Neurosci 2013 33(7), 3079-93. Sorafenib purchased from Selleck.

  • Sorafenib in combination with metformin or the AMPK activator salicylate enhances AMPK activation. a, b, AMPK activation with the combination of sorafenib and metformin in LKB1 mutant KRAS mutant (A549 and H460) NSCLC cells (a), LKB1 wild-type KRAS mutant (H358) (b, left panel) or LKB1 mutant KRAS wild-type (H838) NSCLC cells (b, right panel). Cells were treated for 48 hr with sorafenib (1-3 uM), metformin (1–1.5 mM) or the combination of sorafenib and metformin with the same concentrations as were used for the individual treatments. c, AMPK activation with the combination of sorafenib and salicylate in LKB1 mutant KRAS mutant (A549 and H460) or LKB1 mutant KRAS wild-type (H838) NSCLC cells. Cells were treated for 48 hr with sorafenib (1–3 uM), salicylate (1–1.5 mM) or the combination of sorafenib and salicylate with the same concentrations as were used for the individual treatments. Cell lysates were harvested for western blot analysis and probed with the indicated antibodies.

    Int J Cancer 2012 10.1002/ijc.29113.. Sorafenib purchased from Selleck.

    Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.

    Mol Cancer Res 2014 12(10), 1377-87. Sorafenib purchased from Selleck.

  • HCC cell-derived exosomes reverse sorafenib-induced apoptosis in hepatoma carcinoma cells in vivo. a Tumors from mice treated with PBS (Control), sorafenib (Sora), sorafenib + LO2-exosomes (Sora + LO2 exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib + MHCC-97H-exosomes (Sora + 97H exo) were paraffin-embedded and sectioned, followed by staining of apoptotic cell by using TUNEL assays.

    J Exp Clin Cancer Res, 2016, 35(1):159. Sorafenib purchased from Selleck.

    Sorafenib and PX-866 interact to suppress tumor growth in vivo. Mice were PO administered vehicle diluent, sorafenib (25 mg/kg), PX-866 (2 mg/kg), or the drug combination QD for 3 days. Animals were monitored daily and tumor volume determined every fifth day. Tumors from animals were isolated at day 15 and fixed, sectioned (10-um), and stained against proliferation (Ki67 staining), phospho-ERK1/2 and phospho-AKT staining, the levels of tumor cell apoptosis/cleaved caspase 3, as well as with H&E and 4′,6-diamidino-2-phenylindole (DAPI).

    Mol Pharmacol 2013 84(4), 562-71. Sorafenib purchased from Selleck.

  • Effects of sorafenib or sunitinib on LicA-induced cell death, ER stress responses, PLCc1, Ca2+, and ROS in HepG2 cells. HepG2 cells were pretreated with sorafenib or sunitinib for 1 h, then treated with LicA or TG for 1 h (for P-eIF2a and P-PLCc1) or 24 h (for CHOP, ATF6a(p90), and caspase-4). The cell lysates were subjected to Western blot analyses using antibodies against CHOP, ATF6a(p90), caspase-4(C), P-eIF2a, and b-actin.

    Apoptosis 2014 19(4), 682-97. Sorafenib purchased from Selleck.

    PLoS One 2013 8(1), e54595. Sorafenib purchased from Selleck.

  • (C) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in HUH-7 and R-HUH-7 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (D) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in SK-HEP-1 and R-SK-HEP-1 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (E) HUH-7 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. (F) SK-HEP-1 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. Data were expressed as mean ± standard deviation of each experiment in triplicate. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. Sorafenib purchased from Selleck.

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述 Sorafenib是Raf-1, B-Raf和VEGFR-2的多重激酶抑制剂,无细胞试验中IC50分别为6 nM, 22 nM和90 nM。
靶点
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
体外研究

Sorafenib抑制野生型和V599E突变型B-Raf活性,IC50分别为22 nM 和 38 nM。Sorafenib也能有效抑制mVEGFR2 (Flk-1),mVEGFR3,mPDGFRβ,Flt3,和c-Kit,IC50分别为15 nM,20 nM,57 nM,58 nM,和68 nM。Sorafenib 能够较弱地抑制FGFR-1,IC50 为580 nM。Sorafenib对ERK-1,MEK-1,EGFR,HER-2,IGFR-1,c-Met,PKB,PKA,cdk1/cyclinB,PKCα,PKCγ,和pim-1没有活性。Sorafenib显著抑制NIH 3T3细胞中VEGFR2磷酸化,IC50 为 30 nM,也会抑制HEK-293细胞中Flt-3磷酸化,IC50 为20 nM。Sorafenib有效阻断大多数细胞中MEK 1/2 和 ERK 1/2磷酸化,但不阻断A549 或 H460细胞中该过程,同时不影响PKB通路的抑制。Sorafenib抑制HAoSMC 和 MDA-MB-231细胞的增殖,IC50分别为0.28 μM 和 2.6 μM。[1]除了抑制RAF/MEK/ERK信号通路,Sorafenib tosylate显著抑制eIF4E的磷酸化作用,并以MEK/ERK依赖的方式下调肝癌(HCC)细胞中Mcl-1水平。Sorafenib 抑制PLC/PRF/5 和HepG2细胞的增殖,IC50分别为6.3 μM 和 4.5 μM,并诱导显著的细胞凋亡。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 M3XtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV6y[XJ1UUN3ME2wMlAxODByM{CzJO69VQ>? M4DSNHNCVkeHUh?=
MONO-MAC-6 M4e1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M325e2lEPTB;MD6wNFQyQCEQvF2= MlLJV2FPT0WU
ALL-PO NHXVUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnKTWM2OD1yLkCzNVg1KM7:TR?= NIrFe3pUSU6JRWK=
NKM-1 NEC2Z29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvWfHZKSzVyPUCuNFc1OTZizszN MUjTRW5ITVJ?
CGTH-W-1 Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLPTWM2OD1yLkK1NFIzKM7:TR?= NH;5UI9USU6JRWK=
BB65-RCC M2LZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvZO3JVUUN3ME2wMlQ4ODd|IN88US=> M4LKUXNCVkeHUh?=
NOS-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j4UGlEPTB;MD61OlM3KM7:TR?= M161cHNCVkeHUh?=
SH-4 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn34TWM2OD1yLk[1OlE{KM7:TR?= NWPLUJVmW0GQR1XS
HOP-62 MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr1bmFKSzVyPUCuPFUxQDhizszN NYDBeVBUW0GQR1XS
HCC2998 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljMTWM2OD1yLki4PFE5KM7:TR?= NGfiOFBUSU6JRWK=
GDM-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37CS2lEPTB;MD65NFY6QCEQvF2= MorKV2FPT0WU
KM12 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPsfWhEUUN3ME2xMlAzODl6IN88US=> M{f1b3NCVkeHUh?=
LB2518-MEL M1q5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\UTWM2OD1zLkKwPFA6KM7:TR?= NVrzdZRHW0GQR1XS
NCI-H1436 NWrhWYN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vhO2lEPTB;MT6yNVY4QCEQvF2= NGi4fZNUSU6JRWK=
EM-2 Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT0V3FKSzVyPUGuN|U2PzhizszN MlS2V2FPT0WU
LAMA-84 NVjZbol[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LZPWlEPTB;MT6zO|Y1QCEQvF2= NYCyXoNNW0GQR1XS
KG-1 NGDM[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\yPIt5UUN3ME2xMlQ4QTN3IN88US=> M1fuT3NCVkeHUh?=
A388 NV7he5hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvKTWM2OD1zLkW5NVY2KM7:TR?= NXPGSIhPW0GQR1XS
no-10 NYLGOo9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe1[21NUUN3ME2xMlYyPzJ4IN88US=> NX7MNlkxW0GQR1XS
SF126 Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{O0XmlEPTB;MT62N|gyOiEQvF2= NI\PRpJUSU6JRWK=
MEG-01 NWe2dpA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fM[2lEPTB;MT64NFk5KM7:TR?= M1jzbHNCVkeHUh?=
A3-KAW M2jpdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTFwOEi0NkDPxE1? M1;UPHNCVkeHUh?=
D-247MG NVz2S|AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTCTWM2OD1{LkG0OFgh|ryP MkPjV2FPT0WU
OVCAR-4 NGDRbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7TUldKSzVyPUKuNlE{QTNizszN NHjtTZlUSU6JRWK=
NCI-SNU-1 M{n6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjY[WtKSzVyPUKuN|E3OiEQvF2= Mk\2V2FPT0WU
NCI-H2171 M4DYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITmNI9KSzVyPUKuN|k4PjRizszN NXLoWVByW0GQR1XS
SIG-M5 MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX2cmRKSzVyPUKuOFIzPDJizszN MmjyV2FPT0WU
BE-13 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET6fYdKSzVyPUKuOlk3ODlizszN NWeyeYI6W0GQR1XS
K052 NVXsNnZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nDVmlEPTB;Mj63OFYyPiEQvF2= M1P1WXNCVkeHUh?=
L-540 NUi4TFFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3NRYYxUUN3ME2yMlc2Pzh7IN88US=> Ml\DV2FPT0WU
KMOE-2 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnXTWM2OD1{LkixN|Uh|ryP NU\2WmlNW0GQR1XS
MFH-ino MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HnbGlEPTB;Mj65NlE5PSEQvF2= NYmwe4JiW0GQR1XS
HL-60 M33xe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7xemd2UUN3ME2zMlA3Ojl7IN88US=> MUTTRW5ITVJ?
HCC2218 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXFTWM2OD1|LkGyNFA{KM7:TR?= MWHTRW5ITVJ?
TE-5 MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoO5TWM2OD1|LkGzNVYzKM7:TR?= NFfHdHRUSU6JRWK=
MZ1-PC NUPYbll2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX2ZmxKSzVyPUOuOFc2ODlizszN MYPTRW5ITVJ?
MRK-nu-1 NXTjRZB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\hTWM2OD1|Lk[xOFY5KM7:TR?= MVTTRW5ITVJ?
MZ7-mel NFTRS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\jN2lEPTB;Mz62OlA6QSEQvF2= M4rBfXNCVkeHUh?=
BC-1 NHjqXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK0TWM2OD1|Lke0NFIh|ryP MVzTRW5ITVJ?
ST486 Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvSS|FKSzVyPUOuPFM3PzNizszN MmTJV2FPT0WU
KS-1 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;MW4JKSzVyPUOuPFgyQThizszN M3fUdXNCVkeHUh?=
SK-NEP-1 NHzmXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTRwMU[4NVUh|ryP MmWwV2FPT0WU
BC-3 M2PNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljyTWM2OD12LkKzN|kyKM7:TR?= MkPVV2FPT0WU
NCI-H1581 NF3qOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTRwMki3PVgh|ryP M1\MWHNCVkeHUh?=
MHH-PREB-1 MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu2XW51UUN3ME20MlQxPDh2IN88US=> MVzTRW5ITVJ?
NOMO-1 MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTRwNEi5NFUh|ryP MVPTRW5ITVJ?
QIMR-WIL NEPZfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\PfGNKSzVyPUWuNFczQTRizszN MnjnV2FPT0WU
SF539 M1W1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlSyTWM2OD13LkGzNlI4KM7:TR?= MlrhV2FPT0WU
TE-12 NUTmcIJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7UT2lNUUN3ME21MlI1QTJ7IN88US=> MoLkV2FPT0WU
NCI-H510A MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInJdWJKSzVyPUWuOFE3QDVizszN NEj3VZlUSU6JRWK=
JAR Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjMdY83UUN3ME21MlUxQDJ2IN88US=> NH6xbYZUSU6JRWK=
no-11 NXHhSlFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{mwVmlEPTB;NT63N|U3QCEQvF2= NYHjfYQzW0GQR1XS
BV-173 M3z0VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PhdmlEPTB;NT65OVY5OiEQvF2= NVfhUGZZW0GQR1XS
SR MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1WwOmlEPTB;Nj6wNFY4QCEQvF2= M4HZRnNCVkeHUh?=
MOLT-16 NUXKVVlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITaVJJKSzVyPU[uNlUzPjZizszN NHvTdVZUSU6JRWK=
MZ2-MEL MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DpSmlEPTB;Nj6zNVg{QSEQvF2= MV;TRW5ITVJ?
SW954 M3;tVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzHVmR{UUN3ME22MlQ2QDZ4IN88US=> M2TJO3NCVkeHUh?=
ML-2 NGTWcHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTZwNUK4OFkh|ryP NHS4[3BUSU6JRWK=
OCI-AML2 Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HvXGlEPTB;Nj62NVA3OiEQvF2= NYW3cGxjW0GQR1XS
SIMA NH7Td|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjZV2RKSzVyPUeuNFAyODFizszN MkLpV2FPT0WU
DOHH-2 NUjkXohwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnne3E5UUN3ME23MlA2Pjd4IN88US=> NUDFW5ZSW0GQR1XS
697 MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHKxbWtKSzVyPUeuNFU6QDlizszN NWXVNppxW0GQR1XS
NB1 NUSxRmE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml2wTWM2OD15LkSwOFA4KM7:TR?= NWnzcFJ2W0GQR1XS
D-392MG MoLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT3TWM2OD15Lk[yOlY{KM7:TR?= NWj6bHhvW0GQR1XS
ES8 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInOcIJKSzVyPUeuO|Y2ODNizszN MnfNV2FPT0WU
RPMI-8226 NVmwSlRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T0dGlEPTB;Nz64OFUyOSEQvF2= MlfLV2FPT0WU
IST-MEL1 MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\He20xUUN3ME24MlQxODB{IN88US=> MlvhV2FPT0WU
NB14 M2PiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRThwNkOxN|Mh|ryP NXe0[2g3W0GQR1XS
HD-MY-Z NIDWdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT1XJNKSzVyPUiuOlM4PDZizszN NX;jc3N2W0GQR1XS
TE-10 M3nzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrjfZAzUUN3ME24Mlc3OzV|IN88US=> NFzqUlhUSU6JRWK=
LC-1F NEXzPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TtWWlEPTB;OT6xNFg{PCEQvF2= NUDWPHRmW0GQR1XS
OS-RC-2 NIfSTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTlwMUGyOFMh|ryP MlrLV2FPT0WU
NCI-SNU-16 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTlwMkGwNlYh|ryP MWnTRW5ITVJ?
SHP-77 NF7Xd|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3VemRKUUN3ME25MlcyPjZ{IN88US=> NF3Te5ZUSU6JRWK=
A4-Fuk MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHUTVVpUUN3ME25Mlc2PjFizszN NFPnR4hUSU6JRWK=
NB6 Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTIVXRUUUN3ME25Mlc3ODJ7IN88US=> MX;TRW5ITVJ?
JiyoyeP-2003 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFyLkS3OFUh|ryP MXPTRW5ITVJ?
DMS-114 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LJOmlEPTB;MUCuOVQ1OSEQvF2= NVOzZ4M2W0GQR1XS
NB7 NIHmfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHuTWM2OD1zMD63OVI3KM7:TR?= Mk\ZV2FPT0WU
NCI-H747 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnUT4tFUUN3ME2xNU4yOjF4IN88US=> M2\lVHNCVkeHUh?=
HH NHL4eVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFzLkO4O|Yh|ryP MlG3V2FPT0WU
EW-18 NGTJfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD3TWM2OD1zMT65NFQ1KM7:TR?= MoCwV2FPT0WU
CHP-126 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnnRos1UUN3ME2xNU46PzN6IN88US=> NXToe3BuW0GQR1XS
NTERA-S-cl-D1 M{LuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF{LkCyO|gh|ryP M2nmdHNCVkeHUh?=
DEL NFG4T45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrPTWM2OD1zMj6wPVg2KM7:TR?= NV75[It[W0GQR1XS
LU-139 MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF{LkW0NVMh|ryP MVzTRW5ITVJ?
P30-OHK M{LxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jrdGlEPTB;MUKuOVQ4QSEQvF2= NH;6cWRUSU6JRWK=
NCI-H1522 MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYK5Snl3UUN3ME2xNk44PDZizszN M{Xxe3NCVkeHUh?=
NCI-H1299 NWL4RZV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTzU|FFUUN3ME2xN{4zQTFzIN88US=> NVi3copzW0GQR1XS
UACC-257 Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj4e|RKSzVyPUGzMlUyOjZizszN M2jCOnNCVkeHUh?=
Calu-6 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDIc45pUUN3ME2xN{43ODR4IN88US=> MkX0V2FPT0WU
NCI-H1882 NFHzdoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXjTXJKSzVyPUGzMlg2PTVizszN M3;mNHNCVkeHUh?=
BB30-HNC NGT5b5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljnTWM2OD1zND6wOlA6KM7:TR?= MkPqV2FPT0WU
ES1 MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XRfGlEPTB;MUSuNVU2OSEQvF2= M1HXfXNCVkeHUh?=
NCI-H1694 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XUcWlEPTB;MUSuOFgyOSEQvF2= NULnVG9kW0GQR1XS
IST-SL1 NIHqXmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF2Lkm2NVYh|ryP MYPTRW5ITVJ?
ECC4 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu2cmFKSzVyPUG1MlA2PThizszN NGHMdJVUSU6JRWK=
MDA-MB-134-VI NI\1O5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHHfHlKSzVyPUG1MlQyOzFizszN M{XLbnNCVkeHUh?=
SCH M2LPcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\2ZVVzUUN3ME2xOU41PzJ6IN88US=> NHfPXVFUSU6JRWK=
SK-N-FI NF21V4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXJTWM2OD1zNT62OVM1KM7:TR?= NELPPXlUSU6JRWK=
HDLM-2 NFn3SXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF4LkC3NVQh|ryP NWO3Tm0yW0GQR1XS
Ramos-2G6-4C10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDVTWM2OD1zNj6xNlk4KM7:TR?= NUGyTZVPW0GQR1XS
EW-24 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[yTWM2OD1zNj6xOlYyKM7:TR?= MV3TRW5ITVJ?
NCI-H2141 NE[xT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfGTWM2OD1zNj6xPFkh|ryP M3u4fXNCVkeHUh?=
LC4-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XZTmlEPTB;MU[uOlEyQSEQvF2= NGC2O45USU6JRWK=
HT-144 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj4WVBKSzVyPUG3MlAxPiEQvF2= M2TETnNCVkeHUh?=
SK-MEL-1 NWriR2VoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPjdIlKSzVyPUG3MlAxPzJizszN M3XFOHNCVkeHUh?=
SCC-15 MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi2enVwUUN3ME2xO{4yPjN6IN88US=> M{nybnNCVkeHUh?=
C8166 NVnXc3dqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTMTWM2OD1zNz62PFM{KM7:TR?= NWPCOYtxW0GQR1XS
GOTO NVu4XHdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmGyTWM2OD1zNz64N|Q1KM7:TR?= MmfEV2FPT0WU
COR-L279 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPuS4dKUUN3ME2xPE4yOzZ{IN88US=> M{\1VXNCVkeHUh?=
K-562 M1P1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1G1eWlEPTB;MUiuO|E1OyEQvF2= NGTIZWtUSU6JRWK=
ES3 Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF6LkiwOFEh|ryP MUXTRW5ITVJ?
LU-165 M4SxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF7LkewNFgh|ryP MYnTRW5ITVJ?
KM-H2 MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJyLkOxPFQh|ryP NFvDeppUSU6JRWK=
RL NWjG[JJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7xVWJKSzVyPUKwMlk3QTJizszN M3[5bXNCVkeHUh?=
EW-3 NHXOZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTnTWM2OD1{MT6xPFg6KM7:TR?= MmjSV2FPT0WU
A101D MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfQTWM2OD1{MT6zO|UzKM7:TR?= M4T3RnNCVkeHUh?=
HUTU-80 NW\oVWZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHVVYptUUN3ME2yNU4{QTR4IN88US=> NUjhRpdDW0GQR1XS
NCI-H23 M1nSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXhTWM2OD1{MT6zPVkzKM7:TR?= M2DVUnNCVkeHUh?=
PF-382 NIHBb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJzLkS0NFMh|ryP NYfpOpExW0GQR1XS
LB373-MEL-D NFzNc3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJzLkW2NVUh|ryP NHXYNFBUSU6JRWK=
TE-8 MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPuTWM2OD1{MT62N|k1KM7:TR?= MnHFV2FPT0WU
TE-9 M2fvdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJzLki1NVMh|ryP MYHTRW5ITVJ?
Daudi NHW3RXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX22OHlnUUN3ME2yNU46OzB2IN88US=> Mn:0V2FPT0WU
D-542MG MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJ{LkCyOVYh|ryP NXvjbZIyW0GQR1XS
U-698-M MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjOTWM2OD1{Mj60OlA{KM7:TR?= M3i1cHNCVkeHUh?=
ES6 NFz0[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJ{LkezOlYh|ryP M3XxZ3NCVkeHUh?=
DU-4475 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP5dHY2UUN3ME2yN{45QDl5IN88US=> MoHHV2FPT0WU
ECC12 MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjGfJdKSzVyPUK0MlI5ODNizszN MVXTRW5ITVJ?
C2BBe1 MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M16wWWlEPTB;MkSuN|I{QSEQvF2= NX23TJBoW0GQR1XS
IST-SL2 NVn0NlRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJ2LkSzOlIh|ryP NYe5S2ZiW0GQR1XS
DJM-1 MmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJ2LkWyNlEh|ryP MnX5V2FPT0WU
DMS-153 MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPsTWM2OD1{ND64OlE1KM7:TR?= M1fINHNCVkeHUh?=
NB13 NWXrU|dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrhe5pDUUN3ME2yOU4xOjZ3IN88US=> M2jLR3NCVkeHUh?=
SK-N-DZ NX\oWI4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TmdmlEPTB;Mk[uN|QyPCEQvF2= M16ySHNCVkeHUh?=
COR-L88 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJ4LkW3PVYh|ryP NFHFbJRUSU6JRWK=
LU-65 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXPTWM2OD1{Nj64OVM2KM7:TR?= MW\TRW5ITVJ?
TGBC1TKB Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS1TWM2OD1{Nj65PFI5KM7:TR?= NV;2NGxvW0GQR1XS
THP-1 MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn6wTWM2OD1{Nz6yNVQyKM7:TR?= M3jSR3NCVkeHUh?=
ONS-76 NYPlWVVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJ5LkOzNkDPxE1? MWDTRW5ITVJ?
LC-2-ad MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTQeHp7UUN3ME2yO{43OjNzIN88US=> MmPnV2FPT0WU
EW-13 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPEWIdVUUN3ME2yPU4yPzR4IN88US=> NGDWbVFUSU6JRWK=
MS-1 MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjvTWM2OD1|MD63Nlc5KM7:TR?= NUH4W5JmW0GQR1XS
NCI-H2227 NF;OUY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7ZXGhKSzVyPUOwMlk5ODZizszN NH3iOYFUSU6JRWK=
LXF-289 NXfRV49uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fhT2lEPTB;M{GuOFQ6OiEQvF2= M4LTNXNCVkeHUh?=
MC116 NULXSol{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;mTWM2OD1|Mj6wPFI3KM7:TR?= NFrt[49USU6JRWK=
EVSA-T M{jRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13nNWlEPTB;M{KuNlU5PSEQvF2= NGnNPWtUSU6JRWK=
CTB-1 MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTN|LkGxNFEh|ryP NV;nbFJyW0GQR1XS
COLO-320-HSR MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mom1TWM2OD1|Mz6xOlA{KM7:TR?= MnTlV2FPT0WU
NCI-H2196 NYfuWFhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moj6TWM2OD1|Mz6yOVU4KM7:TR?= M1niOHNCVkeHUh?=
LB2241-RCC M1vGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLJZpBKSzVyPUOzMlMyOzVizszN NVXDeWMyW0GQR1XS
LS-513 NIfUR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLFTWM2OD1|Mz64OlM5KM7:TR?= NHvDVGxUSU6JRWK=
LP-1 M2iydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\GTWM2OD1|Mz65PVU3KM7:TR?= M3r6OnNCVkeHUh?=
A253 NY[2U4ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTN2LkKyPVYh|ryP MUDTRW5ITVJ?
SK-MM-2 NV33eYx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTN2Lkm0OVEh|ryP NYq2S|BvW0GQR1XS
NCI-H1963 NFy0ZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFniR|dKSzVyPUO1MlMxPzJizszN MoDXV2FPT0WU
MMAC-SF NV;Fbm5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfm[YFKSzVyPUO1Mlg4QDVizszN NXvnfFY6W0GQR1XS
LB831-BLC NXHhToY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPveYhKSzVyPUO2MlA3PTRizszN M4DhbXNCVkeHUh?=
WSU-NHL M3jsb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\oO2lEPTB;M{[uNVY1KM7:TR?= MnPQV2FPT0WU
CESS MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;VXWlEPTB;M{[uNlg1QCEQvF2= Ml;3V2FPT0WU
NEC8 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjFe5Y2UUN3ME2zOk42QDN3IN88US=> M3T2c3NCVkeHUh?=
KNS-42 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jSNmlEPTB;M{euNVI{PyEQvF2= MkLZV2FPT0WU
MHH-CALL-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUmxeYNpUUN3ME2zO{4yQDJzIN88US=> MljrV2FPT0WU
K5 NVv1U4JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LjXWlEPTB;M{iuOFMh|ryP MU\TRW5ITVJ?
CP66-MEL NXfoWWVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTN7LkC3N|Mh|ryP NFTQN4VUSU6JRWK=
OPM-2 NWq3dZg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWX2[FJVUUN3ME2zPU45PDN{IN88US=> MmK5V2FPT0WU
IST-MES1 MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX24XpZTUUN3ME20NE4{ODl4IN88US=> NX7SSmdtW0GQR1XS
EC-GI-10 M4fJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTPTWM2OD12MT61PFA2KM7:TR?= NInld3RUSU6JRWK=
CTV-1 MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXSzbZpGUUN3ME20Nk45PDB4IN88US=> Mmi1V2FPT0WU
DG-75 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjGVJBNUUN3ME20N{44PTl3IN88US=> MYrTRW5ITVJ?
KNS-81-FD M1rPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjnTWM2OD12NT60NFU5KM7:TR?= MnT0V2FPT0WU
NCI-H82 NIXJR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\XTWM2OD12NT61O|U5KM7:TR?= M2Tt[nNCVkeHUh?=
RPMI-8866 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ftV2lEPTB;NE[uNVg4OyEQvF2= NUjvNpd1W0GQR1XS
ACN M{Dy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jhN2lEPTB;NE[uOFM1KM7:TR?= NGfUN4hUSU6JRWK=
NCI-H1395 NXPJeoV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[3cmlEPTB;NE[uOFc2PiEQvF2= NWPrenY6W0GQR1XS
NCI-H209 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nGbGlEPTB;NEeuNVQxPSEQvF2= NELaeWVUSU6JRWK=
TGW MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPKZYF2UUN3ME20PU4xPzlzIN88US=> M{X0THNCVkeHUh?=
NCI-H748 NEjKNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\0VHRmUUN3ME20PU41PzV|IN88US=> NYjD[JltW0GQR1XS
EKVX MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTR7Lk[2Nlgh|ryP MYnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

体内研究 Sorafenib(~60 mg/kg)口服给药,对各种人肿瘤异种移植模型,包括MDA-MB-231,Colo-205,HT-29,DLD-1,NCI-H460,和A549表现出广谱的、剂量依赖性抗肿瘤活性,而没有毒性。与抗肿瘤功效相联系,Sorafenib 治疗有效抑制HT-29 和 MDA-MB-231异种移植物中MEK 1/2磷酸化和pERK 1/2水平,但对Colo-205异种移植物没有作用,并且也能显著抑制MDA MB-231,HT-29 和 Colo-205肿瘤异种移植物中肿瘤微血管面积(MVA)和微血管密度(MVD)。[1] 在SCID小鼠体内,Sorafenib治疗对PLC/PRF/5肿瘤异种移植产生剂量依赖性生长抑制,10 mg/kg和30 mg/kg剂量下,TGIs分别为49%和78%,与ERK 和 eIF4E磷酸化抑制,微血管面积减少,和肿瘤细胞凋亡的诱导相一致。[2] Sorafenib通过下调NF-κB介导的Mcl-1 和 cIAP2表达的作用机制使bax-/-细胞对TRAIL剂量依赖性敏感。 Sorafenib (30-60 mg/kg) 与 TRAIL (5 mg/kg)结合对TRAIL抗性HCT116 bax-/-和HT29肿瘤异种移植物表现出显著的功效。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

生化检测:

重组杆状病毒表达的Raf-1 (残基305–648)和 B-Raf (残基 409–765)以融合蛋白纯化。全长人MEK-1由PCR产生,并以大肠杆菌裂解物中的融合蛋白纯化。将Sorafenib加入到含Raf-1 (80纳克),或B-Raf (80 纳克) 以及MEK-1 (1 微克) 混合物的实验缓冲液[20 mM Tris (pH 8.2),100 mM NaCl,5 mM MgCl2,和0.15% β-巯基乙醇]中,DMSO终浓度为1%。加入25微升10 μM γ[33P]ATP (400 Ci/mol)启动Raf激酶试验(终体积50微升),并在32 °C下培育25分钟。磷酸化的MEK-1通过过滤到磷酸纤维素板上采集,使用1%磷酸洗掉未结合的放射性。微波炉加热干燥后,使用β型板计数器量化过滤器结合放射性。人VEGFR2 (KDR)激酶域被表达,并从Sf9裂解物中纯化。VEGFR2的时间分辨荧光分析法能量转移测试在96孔不透明板中以时间分辨荧光分析法能量转移格式进行。最终反应条件如下:1 到10 μM ATP,25 nM poly GT生物素,2 nM 铕标记的磷酸(p)-酪氨酸抗体(PY20),10 nM APC,1% DMSO 终浓度的1 到 7 nM 细胞质激酶域,50 mM HEPES (pH 7.5),10 mM MgCl2,0.1 mM EDTA,0.015% Brij-35,0.1 毫克/毫升BSA,和0.1% β-巯基乙醇。反应体积为100微升,加入酶启动反应。反应启动~1.5 到 2.0小时后,板以615 和 665 nM在Perkin-Elmer VictorV多标记分析仪上读数。信号按如下比率计算:对每孔(665 nm/615 nM) × 10,000。对IC50的产生,在酶起始反应之前加入Sorafenib。50倍的库存板由Sorafenib在50% DMSO/50%蒸馏水溶液中连续稀释制得。最终Sorafenib在1% DMSO中的浓度范围为10 μM 到 4.56 nM。
细胞实验:[1]
+ 展开
  • Cell lines: MDA-MB-231,和 HAoSMC
  • Concentrations: 溶解于DMSO,终浓度为~10 μM
  • Incubation Time: 72小时
  • Method: 细胞在逐渐增加浓度的Sorafenib下暴露72小时。细胞数通过Cell TiterGlo ATP发光测定试剂盒进行定量。该试验通过测定基于细胞中ATP量的发光信号,测量每孔中的活细胞。
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 雌性 NCr-nu/nu 小鼠,皮下植入MDA-MB-231,Colo-205,HT-29,H460,或 A549 细胞
  • Formulation: 以4倍(4 ×储备溶液,稀释为1 ×)溶解于聚氧乙烯蓖麻油/乙醇(50:50)
  • Dosages: ~60 mg/kg
  • Administration: 口服,每天一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 63 mg/mL warmed (135.53 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
5% DMSO+45% PEG 400+ddH2O
3mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 464.82
化学式

C21H16ClF3N4O3

CAS号 284461-73-0
稳定性 powder
别名 BAY 43-9006

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00727233 Completed Neurofibromatosis Type I|Plexiform Neurofibroma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 8, 2008 Phase 1
NCT02989870 Not yet recruiting HepatoCellular Carcinoma|Unresectable HepatoCellular Carcinoma|Liver Cancer H. Lee Moffitt Cancer Center and Research Institute|National Comprehensive Cancer Network April 30, 2017 Phase 1
NCT01445080 Completed Leukemia|With AML and FLT3-ITD Mutations National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 23, 2006 Phase 1
NCT01434602 Recruiting Brain Tumor|Glioblastoma|Anaplastic Glioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 21, 2015 Phase 1|Phase 2
NCT02988440 Not yet recruiting Hepatocellular Carcinoma Novartis Pharmaceuticals|Novartis May 2017 Phase 1
NCT03037437 Not yet recruiting Hepatocellular Cancer The University of Texas Health Science Center at San Antonio January 2017 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Raf Signaling Pathway Map

相关Raf产品

Tags: 购买Sorafenib | Sorafenib供应商 | 采购Sorafenib | Sorafenib价格 | Sorafenib生产 | 订购Sorafenib | Sorafenib代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID